A new study in Annals of Internal Medicine shows that use of antipsychotic drugs is associated with an early and sustained increase in risk of death when used to treat disruptive behavior of older adults with dementia.
University of Leeds scientists have shown how stroke victims could be more vulnerable to Alzheimer’s disease ? years or even decades after making a full recovery.
The University of Washington (UW) announced the creation of the Institute for Health Metrics and Evaluation, a new research center that will conduct independent, rigorous evaluations of health programs worldwide.
The U.S. Food and Drug Administration (FDA) today announced a new advisory committee designed to counsel the agency on how to strengthen the communication of risks and benefits of FDA-regulated products to the public.
Normally sedentary breast cancer survivors who completed an exercise program reduced the levels of insulin in their blood, revealing a likely link between physical activity and better outcomes, researchers from Dana-Farber Cancer Institute in Boston reported at the annual meeting of the American Society of Clinical Oncology in Chicago.
Nutrition 21, Inc. (NASDAQ: NXXI) announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome?, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).
An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.
Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the impressive survival benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.
A clinical trial led and coordinated by Hospital Cl?nic-IDIBAPS, using a drug named Sorafenib, revolutionizes the reality of patients suffering from advanced liver cancer. The results increase overall survival of treated patients by 44 percent in comparison to the control group. The results have been hand selected to be included on the “Best of ASCO” program.
Researchers investigating the evidence for a potential causal link between khat use and mental illness – in the first ever systematic review of the topic – have called for improved research on the stimulant plant, and its possible association with psychiatric disorders.